Betina Biagetti, Marta Araujo-Castro
Journal: Vitamins and hormones 2026;131():41-57
PMID: 41912299
Co-secreting pituitary adenomas (PAs) represent a subset of pituitary tumors with distinct clinical and pathological characteristics. These tumors can secrete both growth hormone (GH) and prolactin (PRL), impacting the clinical presentation, treatment response, and long-term outcomes of acromegaly. This chapter reviews the classification, pathophysiology, and clinical implications of GH and PRL co-secreting PAs, integrating data from previously published studies. Additionally, we discuss treatment strategies, including surgical and medical approaches, highlighting the impact of the treatment with cabergoline and somatostatin receptor ligands (SRLs) in biochemical control. The predictors of surgical and medical treatment resistance, including Knosp grade, tumor size, and baseline hormone levels, are also addressed. Understanding the unique behavior of these tumors is crucial for optimizing treatment strategies and improving patient outcomes.
© 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.